Macie Morse - ONH (second treatment)

Macie Morse received her first round of stem cells in 2008 to treat blindness caused by optic nerve hypoplasia. After this treatment her vision had improved to a level where she could get her driver's license. We caught up with Macie and her mother during a second round of adult stem cell treatments in 2010. Macie's story has been covered extensively by international news outlets. In 2008 a US television production crew attempted an intervention to prevent Macie from coming the first time. Macie's parents raised her without teaching her Braille or focusing much on her blindness. At 15, Macie did not know her visual abilities would keep her out of fighter-pilot school, F1 competition and all other normal driving activities. These interviews were shot while Macie and her family were staying at the hospital in Qingdao.

Improvement statistics

Based on follow-up reports from 115 patients across 276 forms, here is the percentage who self-reported any improvement after treatment.

76%
Light perception
reported improvement · N=100
74%
Nystagmus (uncontrolled eye movement)
reported improvement · N=97
67%
Strabismus (side glances)
reported improvement · N=70
62%
Blindness
reported improvement · N=102
60%
Visual field
reported improvement · N=95
57%
Ability to focus eyes quickly
reported improvement · N=90
57%
Vision in left eye
reported improvement · N=92
56%
Vision in right eye
reported improvement · N=89
54%
Ability to see hand movement
reported improvement · N=91
52%
Ability to see things at a close distance
reported improvement · N=94

About this data

Patients self-assess each symptom on a 5-point scale (Worse / No improvement / Small / Moderate / Significant) at follow-up checkpoints after treatment, comparing to their pre-treatment baseline. "Reported improvement" combines the small, moderate and significant buckets. Data is updated daily from our internal patient registry. As with any medical treatment, past results do not guarantee future outcomes — improvements vary from patient to patient.

Internationally accredited

Held to global laboratory and biologics standards.